September 28, 2020
Video
Ian W. Flinn, MD, PhD, discusses the Bruton’s kinase inhibitors available for patients with B-cell malignancies and how they compare.
June 03, 2015
Article
Ian W. Flinn, MD, PhD, director, Blood Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase I story which examined cerdulatinib in patients with relapsed/refractory B-cell malignancies.
February 09, 2015
Video
Ian W. Flinn, MD, PhD, discusses the mechanism of action and toxicity profile of duvelisib (IPI-145). Duvelisib is being studied for the treatment of hematologic malignancies.
June 05, 2014
Video
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, gives an overview of two ongoing clinical trials looking at IPI-145 for the treatment of hematologic malignancies.